<DOC>
	<DOCNO>NCT00711802</DOCNO>
	<brief_summary>This multi-center , evaluator-blinded , randomize , comparative study design assess safety , efficacy , pharmacokinetics ( PK ) daptomycin pediatric subject age 1 17 year , inclusive , complicate skin skin structure infection ( cSSSI ) cause Gram-positive pathogen .</brief_summary>
	<brief_title>Safety Efficacy Study Daptomycin Pediatric Participants ( 1 17 Years-old ) With Skin Skin Structure Infections</brief_title>
	<detailed_description>This multi-center , evaluator-blinded , randomize , comparative study design assess safety , efficacy , PK daptomycin pediatric participant age 1 17 year , inclusive , cSSSI cause Gram-positive pathogen . Participants enrol age group give age-dependent dos period 14 day . Participants stratify age group receive either daptomycin SOC ( recommend vancomycin , clindamycin semisynthetic penicillin ) ratio 2:1 , respectively . Participants may continue oral therapy follow completion IV study drug administration provide participant meet criteria conversion oral therapy , include clear clinical improvement availability oral agent pathogen susceptible . The choice oral therapy leave discretion Investigator . February 11 , 2015 release post marketing requirement include subject age 3 month - &lt; 1 year . Ref ID : 3701325</detailed_description>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Written parental ( appropriate legal representative ) inform consent prior studyrelated procedure part normal medical care Written participant assent ( appropriate ) Male female age 1 17 year old , inclusive If female childbearing potential ( defined postmenarche ) , lactate pregnant , documented negative pregnancy test result within 48 hour prior study medication administration willing practice reliable birth control measure ( discretion Principal Investigator ) study treatment least 28 day study completion Able comply protocol duration study Skin skin structure infection complicate nature know suspect caused Grampositive pathogen ( ) require IV antibiotic treatment . Complicated infection define infection either involve deep soft tissue require significant surgical intervention ( , infect ulcer , burn , major abscess ) infection participant significant underlying disease state complicate response treatment . The Investigator may contact Medical Monitor discuss infection meet definition otherwise appear appropriate inclusion At least three follow clinical sign symptom associate cSSSI : pain ; tenderness palpation ; temperature &gt; 37.5 degree Celsius ( C ) ( 99.5 degree Fahrenheit [ F ] ) oral &gt; 38 degree C ( 100.4 degree F ) rectal ; white blood count ( WBC ) &gt; 12,000/cubic millimeter ( mm^3 ) â‰¥10 % band ; swell and/or induration ; erythema ( &gt; 1 centimeter [ cm ] beyond edge wound abscess ) ; pu formation Investigational drug use ( include daptomycin ) participation experimental procedure 30 day precede study entry Known allergy/hypersensitivity daptomycin Known infection cause solely Gramnegative pathogen ( ) , fungus ( ) , virus ( e ) Previous systemic antimicrobial therapy exceed 24 hour duration administer anytime 48 hour prior first dose study drug ( exception : participant eligible previous antibiotic without clinical improvement and/or wound culture available pathogen sensitive prior therapy ) Known suspect pneumonia , osteomyelitis , meningitis , endocarditis Known bacteremia ( exception : participant enrol study subsequently find blood culture positive bacteremia may continue ) Participant current know clinically significant abnormal laboratory test result ( include electrocardiogram [ ECGs ] ) would expose participant unacceptable risk determine Investigator History clinically significant cardiovascular , renal , hepatic , pulmonary ( wellcontrolled asthma acceptable ) , gastrointestinal , endocrine , hematological , autoimmune disease , primary immune deficiency ( unless Investigator considers subject would risk participate study [ Note : human immunodeficiency virusinfected participant must enrol ] ) History current clinically significant ( discretion Investigator ) muscular disease , nervous system , seizure disorder Unexplained muscular weakness , history peripheral neuropathy , GuillainBarre syndrome spinal cord injury Known suspect renal insufficiency ( , estimate creatinine clearance rate [ CLcr ] &lt; 80 mL/min/1.73 square meter [ m^2 ] History current rhabdomyolysis History ( within 1 year prior first dose study drug ) current myositis Current septic shock Known suspect creatine phosphokinase ( CPK ) elevation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Complicated</keyword>
	<keyword>Skin</keyword>
	<keyword>Structure</keyword>
</DOC>